Bristol Myers Squibb selected Houston for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through commercial launch. The site is intended to produce multiple modalities—including small molecules, biologics, and antibody-drug conjugates—within the broader Generation Park development. BMS framed the investment as part of a previously announced commitment to invest $40 billion over five years across U.S.-based R&D, technology, and manufacturing. The company also cited the need for domestic capacity and supply chain resilience, as reshoring momentum continues across large biopharma. Industry impact is amplified by the surrounding cluster of U.S. manufacturing expansion plans, including Eli Lilly’s activity at Generation Park and its recent acquisition of Houston ADC-focused CrossBridge Bio—signaling increased manufacturing competition for talent, equipment, and process know-how.